Conduit Pharmaceuticals Valuation
| CDT Stock | 1.20 0.08 7.14% |
Today, the firm appears to be overvalued. Conduit Pharmaceuticals shows a prevailing Real Value of USD1.15 per share. The current price of the firm is USD1.2. Our model approximates the value of Conduit Pharmaceuticals from analyzing the firm fundamentals such as Return On Asset of -1.09, shares owned by institutions of 2.40 %, and Shares Outstanding of 4.71 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Conduit Pharmaceuticals' valuation include:
Overvalued
Today
Please note that Conduit Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Conduit Pharmaceuticals is based on 3 months time horizon. Increasing Conduit Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Conduit Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 1.20, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.2 | Real 1.15 | Hype 0.83 | Naive 2.05 |
The intrinsic value of Conduit Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Conduit Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Conduit Pharmaceuticals helps investors to forecast how Conduit stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Conduit Pharmaceuticals more accurately as focusing exclusively on Conduit Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Conduit Pharmaceuticals' intrinsic value based on its ongoing forecasts of Conduit Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Conduit Pharmaceuticals' closest peers.
Conduit Pharmaceuticals Cash |
|
Conduit Valuation Trend
Conduit Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Conduit Pharmaceuticals' financial worth over time. Using both Conduit Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Conduit Valuation Data Drivers
Conduit Pharmaceuticals Total Value Analysis
Conduit Pharmaceuticals is currently forecasted to have company total value of 8.16 M with market capitalization of 5.65 M, debt of 1.23 B, and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Conduit Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.16 M | 5.65 M | 1.23 B |
Conduit Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Conduit Pharmaceuticals has an asset utilization ratio of 75.39 percent. This implies that the Company is making USD0.75 for each dollar of assets. An increasing asset utilization means that Conduit Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Conduit Pharmaceuticals Ownership Allocation
Conduit Pharmaceuticals shows 13.92 percent of its outstanding shares held by insiders and 2.4 percent owned by other corporate entities.Conduit Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 2.46 B. Total Income to common stockholders was 198.41 M with profit before taxes, overhead, and interest of 0.About Conduit Pharmaceuticals Valuation
The stock valuation mechanism determines Conduit Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Conduit Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Conduit Pharmaceuticals. We calculate exposure to Conduit Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Conduit Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 830 M | 737.8 M | |
| Pretax Profit Margin | 0.08 | 0.07 | |
| Operating Profit Margin | 0.10 | 0.09 | |
| Net Profit Margin | 0.07 | 0.06 | |
| Gross Profit Margin | 0.34 | 0.30 |
Conduit Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Conduit Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 41.3 M | |
| Shares Float | 636.4 K |
Conduit Pharmaceuticals Current Valuation Indicators
Conduit Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Conduit Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Conduit Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Conduit Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Conduit Pharmaceuticals' worth.Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.